Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
French Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Roche Diagnostics has received FDA Emergency use approval for its highly specific Elecsys antibody test.
Belgian Bone Therapeutics SA has secured €11m to foster development of its late stage pipeline candidates.